网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
不同生物标志物联合诊断骨肉瘤的价值
作者:陈汉文  高书明  辛大森  程才 
单位:沧州市中心医院 骨一科, 河北 沧州 061001
关键词:骨肉瘤 T细胞免疫球蛋白黏蛋白分子3 微RNA-21 碱性磷酸酶 乳酸脱氢酶 诊断效能 
分类号:R738.1;R730.43
出版年·卷·期(页码):2020·39·第三期(352-356)
摘要:

目的:探究不同生物标志物在骨肉瘤患者中的表达水平及诊断价值。方法:对2014年5月至2017年12月在本院就诊的56例骨肉瘤患者(骨肉瘤组)、62例良性骨科增生患者(良性疾病组)及62例健康体检者(对照组)进行分析,比较3组之间T细胞免疫球蛋白黏蛋白分子3(Tim-3)、miRNA-21(miR-21)、碱性磷酸酶(ALP)及乳酸脱氢酶(LDH)水平差异,并以ROC曲线评价其单独及联合诊断的诊断效能。结果:3组患者的Tim-3、miR-21、ALP及LDH水平间差异有统计学意义(P<0.05)。ROC曲线显示,Tim-3及miR-21联合诊断的AUC为0.929,显著高于单独诊断(P<0.05);Tim-3、miR-21、ALP、LDH水平的最佳截点分别为12.37 ng·ml-1、1.60拷贝·μl-1、239.84 U·L-1、266.91 U·L-1,联合诊断的敏感性及阳性预测值均显著高于单独诊断(P<0.05)。结论:Tim-3及miR-21联合诊断骨肉瘤具有较高的价值,其中ρ(Tim-3)≥ 12.37 ng·ml-1、miR-21水平≥ 1.60拷贝·μl-1可以作为骨肉瘤筛查截点。

Objective: To explore the clinical value of different biomarkers in the diagnosis of osteosarcoma.Methods: 56 patients with osteosarcoma from May 2014 to December 2017 diagnosed in our hospital (osteosarcoma group), 62 patients with orthopedic benign hyperplasia (benign disease group) and 62 cases of healthy subjects (control group) within the same period of time and of age were selected. T cell immunoglobulin and mucin domain-3(Tim-3), microRNA-21(miR-21), alkaline phosphatase (ALP), lactate dehydrogenase (LDH)level in the three groups were comparatively analyzed, receiver operating curve (ROC) was drawn and the diagnostic efficacy of Tim-3, miR-21, ALP, LDH alone and in combination with the diagnosis of osteosarcoma were evaluated. Results: There was a statistically significant difference in levels of Tim-3, miR-21, ALP, LDH in the three groups (P<0.05). The ROC curve showed that the AUC of combined Tim-3 and miR-21 was 0.929, it was significantly higher than that of single diagnosis. The optimal cut-off point of Tim-3 was 12.37 ng·ml-1, miR-21 was 1.60 copies·μl-1, ALP was 239.84 U·L-1, LDH was 266.91 U·L-1. Using the above cut-off points, the sensitivity and positive predictive value of combined diagnosis were significantly higher than single diagnosis(P<0.05).Conclusion: Tim-3 combined with miR-21 has a higher value in the diagnosis of osteosarcoma, wherein Tim-3 ≥ 12.37 ng·ml-1, miR-21 ≥ 1.60 copies·μl-1 can be regarded as the best cut-off point for osteosarcoma screening.

参考文献:

[1] LI J,YANG Z,LI Y,et al.Cell apoptosis,autophagy and necroptosis in osteosarcoma treatment[J]. Oncotarget,2016,7(28):44763-44778.
[2] LAMPLOT J D,DENDULURI S,QIN J,et al.The current and future therapies for human osteosarcoma[J]. Curr Cancer Ther Rev,2013,9(1):55-77.
[3] DAS M,ZHU C,KUCHROO V K.Tim-3 and its role in regulating anti-tumor immunity[J]. Immunol Rev,2017,276(1):97-111.
[4] CHANG J,YAO M,LI Y,et al.MicroRNAs for osteosarcoma in the mouse:a meta-analysis[J]. Oncotarget,2016,7(51):85650-85674.
[5] JI F,FU S J,GUO Z Y,et al.Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma[J].Medicine (Baltimore),2016,95(27):e4065.
[6] 中国临床肿瘤学会(CSCO)骨肉瘤专家委员会,中国抗癌协会肉瘤专业委员会.经典型骨肉瘤临床诊疗专家共识[J].临床肿瘤学杂志,2012,17(10):931-933.
[7] 王春燕,汤丽娜,祁伟祥,等.伽玛刀治疗40例骨肉瘤肺转移患者的生存分析[J].中华肿瘤防治杂志,2015,22(8):633-636.
[8] 黄成校,郭卫春,郭哲.骨肉瘤的治疗进展[J].医学综述,2013,19(11):65-68.
[9] 金璐,郭涛.T细胞免疫球蛋白粘蛋白家族Tim-3分子与肿瘤免疫[J].国际免疫学杂志,2013,36(1):28-31.
[10] 荆玉龙,吕智.微RNA在骨肉瘤中的研究进展[J].肿瘤研究与临床,2016,28(9):638-641.
[11] 樊根涛,蔡滕,周光新,等.骨肉瘤治疗前血清乳酸脱氢酶和碱性磷酸酶浓度与预后的相关性[J].医学研究生学报,2013,26(7):734-737.
[12] YU M,LU B,LIU Y,et al.Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates anoikis[J]. Mol Med Rep,2017,15(3):1103-1108.
[13] NAMLØS H M,MEZA-ZEPEDA L A,BARØY T,et al.Modulation of the osteosarcoma expression phenotype by microRNAs[J]. PLoS One,2012,7(10):e48086.
[14] HU K,WANG Z,LIN P,et al.Three hematological indexes that may serve as prognostic indicators in patients with primary,high-grade,appendicular osteosarcoma[J]. Oncotarget,2017,8(26):43130-43139.
[15] GONÇALVES S I,YASINSKA I M,SAKHNEVYCH S S,et al.The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells[J]. EBioMedicine,2017,22(7):44-57.
[16] GAUTRON A S,DOMINGUEZ-VILLAR M,de MARCKEN M,et al.Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells[J]. Eur J Immunol,2014,44(9):2703-2711.
[17] CAO Y,ZHOU X,HUANG X,et al.Tim-3 expression in cervical cancer promotes tumor metastasis[J]. PLoS One,2013,8(1):e53834.
[18] CANFRÁN-DUQUE A,ROTLLAN N,ZHANG X,et al.Macrophage deficiency of miR-21 promotes apoptosis,plaque necrosis,and vascular inflammation during atherogenesis[J]. EMBO Mol Med,2017,9(9):1244-1262.
[19] MARKOU A,ZAVRIDOU M,LIANIDOU E S.miRNA-21 as a novel therapeutic target in lung cancer[J]. Lung Cancer (Auckl),2016,7(2):19-27.
[20] KIM S H,SHIN K H,MOON S H,et al.Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma[J]. Cancer Med,2017,6(6):1311-1322.
[21] LI G,GAO J,TAO Y L,et al.Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma[J]. Chin J Cancer,2012,31(4):197-206.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 730004 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541